Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue

ELI LILLY & Co

2024-FY EPS reported $11.71 revenue$45,042,700,000

Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).
Revenue growth driven by volume from Mounjaro and Zepbound; non-incretin revenue grew 20%.
2025 guidance: revenue $58.0-61.0B, reported EPS $22.05-23.55, non-GAAP EPS $22.50-24.00.
Pipeline: FDA approved Zepbound for OSA and Omvoh for Crohn's; Kisunla approved in China.
Board authorized $15B share repurchase program and 15% dividend increase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.